A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

So, what's the tea on microdosing? It's pretty much what it sounds like — taking smaller doses than the usual prescribed ...

So the, the question we're investigating in this study is whether the use of GLP-1 receptor agonists, which is *** medication for weight loss and diabetes, um, is associated with *** lower risk of ...

already declared that shortages of popular GLP-1 medications have ended, CNN reported. Those medications include semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound).

The FDA has banned compounded versions of GLP-1 ... of semaglutide injections sold by Novo Nordisk under the brand names Ozempic and Wegovy, as well as tirzepatide injections Zepbound and Mounjaro ...

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN reported. Those medications include semaglutide (Ozempic and Wegovy) and ...